The toxicology of aflatoxins as a basis for public health decisions

Mutagenesis

Volumn 17, Issue 6, 2002, Pages 471-481

  Wild, C P ^a   Turner, P C ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AFLATOXIN; AFLATOXIN B1; ALDEHYDE REDUCTASE; BIOLOGICAL MARKER; CARCINOGEN; CHLOROPHYLL; DNA; GLUTATHIONE TRANSFERASE; OLTIPRAZ; PLACEBO; PROTEIN P53; TUMOR SUPPRESSOR PROTEIN; MUTAGENIC AGENT;

AGRICULTURAL MANAGEMENT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; CANCER RISK; CARCINOGENICITY; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DIETARY INTAKE; DISEASE COURSE; DNA ADDUCT; ENVIRONMENTAL EXPOSURE; ENZYME INDUCTION; GENE MUTATION; HUMAN; HUMAN CELL; LIVER CARCINOMA; MEDICAL DECISION MAKING; MEDICAL RESEARCH; MOLECULAR MECHANICS; MUTAGENICITY; NONHUMAN; POPULATION RESEARCH; PRIMARY PREVENTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PUBLIC HEALTH SERVICE; RAT; REVIEW; RISK MANAGEMENT; TOXICOKINETICS; TOXICOLOGY; ANIMAL; DRUG EFFECT; GENETICS; HEPATITIS B VIRUS; LIVER CELL CARCINOMA; LIVER TUMOR; METABOLISM; MUTATION; PATHOGENICITY; PUBLIC HEALTH; TUMOR SUPPRESSOR GENE;

ANIMALIA;

AFLATOXINS; ANIMALS; BIOLOGICAL MARKERS; CARCINOGENS; CARCINOMA, HEPATOCELLULAR; DNA; DNA ADDUCTS; GENES, P53; HEPATITIS B VIRUS; HUMANS; LIVER NEOPLASMS; MUTAGENS; MUTATION; PUBLIC HEALTH;

EID: 0036856464     PISSN: 02678357     EISSN: None     Source Type: Journal    
DOI: 10.1093/mutage/17.6.471     Document Type: Review

References (153)

1. Allen, S.J., Wild, C.P., Wheeler, J.G., Riley, E.M., Montesano, R., Bennett, S., Whittle, H.C. and Hall, A.J. (1992) Aflatoxin exposure malaria and hepatitis B infection in rural Gambian children. Trans. R. Soc. Trop. Med. Hyg., 86, 426-430.
2. Bailey, E.A., Iyer, R.S., Stone, M.P., Harris, T.M. and Essigmann, J.M. (1996) Mutational properties of the primary aflatoxin B1-DNA adduct. Proc. Natl Acad. Sci. USA, 93, 1535-1539.
3. Banerjee, R., Caruccio, L., Zhang, Y.J., McKercher, S. and Santella, R.M. (2000) Effects of carcinogen-induced transcription factors on the activation of hepatitis B virus expression in human hepatoblastoma HepG2 cells and its implication on hepatocellular carcinomas. Hepatology, 32, 367-374.
4. Bannasch, P., Khoshkhou, N.I., Hacker, H.J. et al. (1995) Synergistic hepatocarcinogenic effect of hepadnaviral infection and dietary aflatoxin B1 in woodchucks. Cancer Res., 55, 3318-3330.
5. Barraud, L., Guerret, S., Chevallier, M., Borel, C., Jamard, C., Trepo, C., Wild, C.P. and Cova, L. (1999) Enhanced duck hepatitis B virus gene expression following aflatoxin B1 exposure. Hepatology, 29, 1317-1323.
6. Battista, J.R. and Marnett, L.J, (1985) Prostaglandin H synthase-dependent epoxidation of aflatoxin B1. Carcinogenesis, 6, 1227-1229.
7. Benasutti, M., Ejadi, S., Whitlow, M.D. and Loechler, E.L. (1988) Mapping the binding site of aflatoxin B1 in DNA: systematic analysis of the reactivity of aflatoxin B1 with guanines in different DNA sequences. Biochemistry, 27, 472-481.
8. Boix-Ferrero, J., Pellin, A., Blesa, R., Adrados, M. and Llombart-Bosch, A. (1999) Absence of p53 gene mutations in hepatocarcinomas from a Mediterranean area of Spain. A study of 129 archival tumour samples. Virchows Arch., 434, 497-501.
9. Bourdon, J.C., Derrico, A., Paterlini, P., Grigioni, W., May, E. and Debuire, B. (1995) p53 protein accumulation in European hepatocellular-carcinoma is not always dependent on p53 gene mutation. Gastroenterology, 108, 1176-1182.
10. Breinholt, V., Arbogast, D., Loveland, P., Pereira, C., Dashwood, R., Hendricks, J. and Bailey, G. (1999) Chlorophyllin chemoprevention in trout initiated by aflatoxin B(1) bath treatment: an evaluation of reduced bioavailability vs. target organ protective mechanisms. Toxicol. Appl. Pharmacol., 158, 141-151.
11. Bressac, B., Kew, M., Wands, J. and Ozturk, M. (1991) Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature, 350, 429-431.
12. Buetler, T.M. and Eaton, D.L. (1992) Complementary DNA cloning, messenger RNA expression, and induction of alpha-class glutathione S-transferases in mouse tissues. Cancer Res., 52, 314-318.
13. Buetow, K.H., Sheffield, V.C., Zhu, M., Zhou, T., Shen, F.M., Hino, O., Smith, M., McMahon, B.J., Lanier, A.P. and London, W.T. (1992) Low frequency of p53 mutations observed in a diverse collection of primary hepatocellular carcinomas. Proc. Natl Acad. Sci. USA, 89, 9622-9626.
14. Cariello, N.F., Cui, L. and Skopek, T.R. (1994) In vitro mutational spectrum of aflatoxin B1 in the human hypoxanthine guanine phosphoribosyltransferase gene. Cancer Res., 54, 4436-4441.
15. Challen, C., Lunec, J., Warren, W., Collier, J. and Bassendine, M.F. (1992) Analysis of the p53 tumor-suppressor gene in hepatocellular carcinomas from Britain. Hepatology, 16, 1362-1366.
16. Chemin, I., Takahashi, S., Belloc, C., Lang, M.A., Ando, K., Guidotti, L.G., Chisari, F.V. and Wild, C.P. (1996) Differential induction of carcinogen metabolizing enzymes in a transgenic mouse model of fulminant-hepatitis. Hepatology, 24, 649-656.
17. Chemin, I., Ohgaki, H., Chisari, F.V. and Wild, C.P. (1999) Altered expression of hepatic carcinogen metabolizing enzymes with liver injury in HBV transgenic mouse lineages expressing various amounts of hepatitis B surface antigen. Liver, 19, 81-87.
18. Chen, S.Y., Chen, C.J., Chou, S.R., Hsieh, L.L., Wang, L.Y., Tsai, W.Y., Ahsan, H. and Santella, R.M. (2001) Association of aflatoxin B(1)-albumin adduct levels with hepatitis B surface antigen status among adolescents in Taiwan. Cancer Epidemiol. Biomarkers Prev., 10, 1223-1226.
19. Chomarat, P., Sipowicz, M.A., Diwan, B.A., Fornwald, L.W., Awasthi, Y.C., Anver, M.R., Rice, J.M., Anderson, L.M. and Wild, C.P. (1997) Distinct time courses of increase in cytochromes P450 1A2, 2A5 and glutathione S-transferases during the progressive hepatitis associated with Helicobacter hepaticus. Carcinogenesis, 18, 2179-2190.
20. Chomarat, P., Rice, J.M., Slagle, B.L. and Wild, C.P. (1998) Hepatitis B virus-induced liver injury and altered expression of carcinogen metabolising enzymes: the role of the HBx protein. Toxicol. Lett., 102/103, 595-601.
21. Coursaget, P., Depril, N., Chabaud, M., Nandi, R., Mayelo, V., LeCann, P. and Yvonnet, B. (1993) High prevalence of mutations at codon 249 of the p53 gene in hepatocellular carcinomas from Senegal. Br. J. Cancer, 67, 1395-1397.
22. Dashwood, R., Negishi, T., Hayatsu, H., Breinholt, V., Hendricks, J. and Bailey, G. (1998) Chemopreventive properties of chlorophylls towards aflatoxin B1: a review of the antimutagenicity and anticarcinogenicity data in rainbow trout. Mutat. Res., 399, 245-253.
23. DeBenedetti, V.M.G., Welsh, J.A., Trivers, G.E., Harpster, A., Parkinson, A.J., Lanier, A.P., McMahon, B.J. and Bennett W.P. (1995) p53 is not mutated in hepatocellular carcinomas from Alaska natives. Cancer Epidemiol. Biomarkers Prev., 4, 79-82.
24. De Flora, S., Hietanen, E., Bartsch, H., Camoirano, A., Izzotti, A., Bagnasco, M. and Millman, I. (1989) Enhanced metabolic activation of chemical hepatocarcinogens in woodchucks infected with hepatitis B virus. Carcinogenesis, 10, 1099-1106.
25. Denissenko, M.F, Koudriakova, T.B., Smith, L., O'Connor, T.R., Riggs, A.D. and Pfeifer, G.P. (1998) The p53 codon 249 mutational hotspot in hepatocellular carcinoma is not related to selective formation or persistence of aflatoxin B1 adducts. Oncogene, 17, 3007-3014.
26. Denissenko, M.F, Cahill, J., Koudriakova, T.B., Gerber, N. and Pfeifer, G.P. (1999) Quantitation and mapping of aflatoxin B1-induced DNA damage in genomic DNA using aflatoxin B1-8,9-epoxide and microsomal activation systems. Mutat. Res., 425, 205-211.
27. Donnelly, P.J., Stewart, R.K., Ali, S.L., Conlan, A.A., Reid, K.R., Petsikas, D. and Massey, T.E. (1996) Biotransformation of aflatoxin B1 in human lung. Carcinogenesis, 17, 2487-2494.
28. Duflot, A., Hollstein, M., Mehrotra, R., Trepo, C., Montesano, R. and Cova, L. (1994) Absence of p53 mutation at codon 249 in duck hepatocellular carcinomas from the high incidence area of Qidong (China). Carcinogenesis, 15, 1353-1357.
29. Dumenco, L., Oguey, D., Wu, J., Messier, N. and Fausto, N. (1995) Introduction of a murine p53 mutation corresponding to human codon 249 into a murine hepatocyte cell line results in growth advantage, but not in transformation. Hepatology, 22, 1279-1288.
30. Eaton, D.L. and Gallagher, E.P. (1994) Mechanisms of aflatoxin carcinogenesis. Annu. Rev. Pharmacol. Toxicol., 34, 135-172.
31. Eaton, D.L. and Groopman, J.D. (1994) The Toxicology of the Aflatoxins: Human Health, Veterinary, and Agricultural Signficance. Academic Press, London, UK.
32. Egner, P.A., Wang, J.B., Zhu, Y.R. et al. (2001) Chlorophyllin intervention reduces aflatoxin-DNA adducts in individuals at high risk for liver cancer. Proc. Natl Acad. Sci. USA, 98, 14601-14606.
33. Forrester, K., Lupold, S.E., Ott, V.L., Chay, C.H., Band, V., Wang, X.W. and Harris, C.C. (1995) Effects of p53 mutants on wild-type p53-mediated transactivation are cell type dependent. Oncogene, 10, 2103-2111.
34. Foster, P.L., Eisenstadt, E. and Miller, J.H. (1983) Base substitution mutations induced by metabolically activated aflatoxin B1. Proc. Natl Acad. Sci. USA, 80, 2695-2698.
35. Fujimoto, Y., Hampton, L.L., Luo, L.D., Wirth, P.J. and Thorgeirsson, S.S. (1992) Low frequency of p53 gene mutation in tumors induced by aflatoxin B1 in nonhuman primates. Cancer Res., 52, 1044-1046.
36. Fujimoto, Y., Hampton, L.L., Wirth, P.J., Wang, N.J., Xie, J.P. and Thorgeirsson, S.S. (1994) Alterations of tumor suppressor genes and allelic losses in human hepatocellular carcinomas in China. Cancer Res., 54, 281-285.
37. Gallagher, E.P., Kunze, K.L., Stapleton, P.L. and Eaton, D.L. (1996) The kinetics of aflatoxin B1 oxidation by human cDNA-expressed and human liver microsomal cytochromes P450 1A2 and 3A4. Toxicol. Appl. Pharmacol., 141, 595-606.
38. 1-8,9-epoxide in woodchucks undergoing chronic active hepatitis. Int. J. Cancer, 73, 587-591.
39. Gopalakrishnan, S., Harris, T.M. and Stone, M.P. (1990) Intercalation of aflatoxin B1 in two oligodeoxynucleotide adducts: comparative 1H NMR analysis of d(ATCAFBGAT).d(ATCGAT) and d(ATAFBGCAT)2. Biochemistry, 29, 10438-10448.
40. Groopman, J.D. and Kensler, T.W. (1999) The light at the end of the tunnel for chemical-specific biomarkers: daylight or headlight? Carcinogenesis, 20, 1-11.
41. Groopman, J.D., Donahue, P.R., Zhu, J.Q., Chen, J.S. and Wogan, G.N. (1985) Aflatoxin metabolism in humans: detection of metabolites and nucleic acid adducts in urine by affinity chromatography. Proc. Natl Acad. Sci. USA, 82, 6492-6496.
42. Groopman, J.D., DeMatos, P., Egner, P.A., Love-Hunt, A. and Kensler, T.W. (1992) Molecular dosimetry of urinary aflatoxin-N7-guanine and serum aflatoxin-albumin adducts predicts chemoprotection by 1,2-dithiole-3-thione in rats. Carcinogenesis, 13, 101-106.
43. Guengerich, F.P., Johnson, W.W., Shimada, T., Ueng, Y.F., Yamazaki, H. and Langouet, S. (1998) Activation and detoxication of aflatoxin B1. Mutat. Res., 402, 121-128.
44. Hayashi, H., Sugio, K., Matsumata, T., Adachi, E., Urata, K., Tanaka, S. and Sugimachi, K. (1993) The mutation of codon-249 in the p53 gene is not specific in Japanese hepatocellular-carcinoma. Liver, 13, 279-281.
45. Hayes, J.D., Judah, D.J., McLellan, L.I., Kerr, L.A., Peacock, S.D. and Neal, G.E. (1991) Ethoxyquin-induced resistance to aflatoxin B1 in the rat is associated with the expression of a novel alpha-class glutathione S-transferase subunit, Yc2, which possesses high catalytic activity for aflatoxin B1-8,9-epoxide. Biochem. J., 279, 385-398.
46. Hayes, J.D., Judah, D.J., Neal, G.E. and Nguyen, T. (1992) Molecular cloning and heterologous expression of a cDNA encoding a mouse glutathione S-transferase Yc subunit possessing high catalytic activity for aflatoxin B1-8,9-epoxide. Biochem. J., 285, 173-180.
47. Hayes, J.D., Judah, D.J. and Neal, G.E. (1993) Resistance to aflatoxin B1 is associated with the expression of a novel aldo-keto reductase which has catalytic activity towards a cytotoxic aldehyde-containing metabolite of the toxin. Cancer Res., 53, 3887-3894.
48. Heinonen, J.T., Fisher, R., Brendel, K. and Eaton, D.L. (1996) Determination of aflatoxin B1 biotransformation and binding to hepatic macromolecules in human precision liver slices. Toxicol. Appl. Pharmacol., 136, 1-7.
49. Hollstein, M.C., Wild, C.P., Bleicher, F., Chutimataewin, S., Harris, C.C., Srivatanakul, P. and Montesano, R. (1993) p53 mutations and aflatoxin B1 exposure in hepatocellular carcinoma patients from Thailand. Int. J. Cancer, 53, 51-55.
50. Hosono, S., Chou, M.J., Lee, C.S. and Shih, C. (1993) Infrequent mutation of p53 gene in hepatitis B virus positive primary hepatocellular carcinomas. Oncogene, 8, 491-496.
51. Hsieh, D.P.H. and Atkinson, D.N. (1995) Recent aflatoxin exposure and mutation at codon 249 of the human p53 gene: lack of association. Food Addit. Contam., 12, 421-424.
52. Hsu, I.C., Metcalf, R.A, Sun, T., Welsh, J.A., Wang, N.J. and Harris, C.C. (1991) Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature, 350, 427-428.
53. Hulla, J.E., Chen, Z.Y. and Eaton, D.L. (1993) Aflatoxin B1-induced rat hepatic hyperplastic nodules do not exhibit a site-specific mutation within the p53 gene. Cancer Res., 53, 9-11.
54. Hustert, E., Haberl, M., Burk, O. et al. (2001) The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics, 11, 773-779.
55. IARC (1993) IARC Monographs on the Evaluation of Carcinogenic Risks to Humans: Some Naturally Occurring Substances: Food Items and Constitutents, Heterocyclic Armonatic Amines and Mycotoxins, IARC Scientific Publications no. 56. IARC, Lyon.
56. IARC (2002) IARC Monographs on the Evaluation of Carcinogenic Risks to Humans: Traditional Herbal Medicines, Some Mycotoxins, Napthalene and Styrene. Vol 82, 2002, in press. IARC, Lyon.
57. Ireland, L.S., Harrison, D.J., Neal, G.E. and Hayes, J.D. (1998) Molecular cloning, expression and catalytic activity of a human AKR7 member of the aldo-keto reductase superfamily: evidence that the major 2-carboxybenzaldehyde reductase from human liver is a homologue of rat aflatoxin B1-aldehyde reductase. Biochem. J., 332, 21-34.
58. Iyer, R.S., Voehler, M.W. and Harris, T.M. (1994) Adenine adduct of aflatoxin B1 epoxide. J. Am. Chem. Soc., 116, 8863-8869.
59. Jackson, P.E., Qian, G.S., Friesen, M.D., Zhu, Y.R., Lu, P., Wang, J.B., Wu, Y., Kensler, T.W., Vogelstein, B. and Groopman, J.D. (2001) Specific p53 mutations detected in plasma and tumors of hepatocellular carcinoma patients by electrospray ionization mass spectrometry. Cancer Res., 61, 33-35.
60. Jacobson, L.P, Zhang, B.C., Zhu, Y.R. et al. (1997) Oltipraz chemoprevention trial in Qidong, People's Republic of China: study design and clinical outcomes. Cancer Epidemiol. Biomarkers Prev., 6, 257-265.
61. Jaitovitch-Groisman, I., Fotouhi-Ardakani, N., Schecter, R.L., Woo, A., Alaoui-Jamali, M.A. and Batist, G. (2000) Modulation of glutathione S-transferase alpha by hepatitis B virus and the chemopreventive drug oltipraz. J. Biol. Chem., 275, 33395-33403.
62. 1 exo-8,9-epoxide and rearrangement of the dihydrodiol. J. Am. Chem. Soc., 118, 8213-8220.
63. Johnson, W.W., Ueng, Y.F., Widersten, M., Mannervik, B., Hayes, J.D., Sherratt, P.J., Ketterer, B. and Guengerich, F.P. (1997a) Conjugation of highly reactive aflatoxin B1 exo-8,9-epoxide catalyzed by rat and human glutathione transferases: estimation of kinetic parameters. Biochemistry, 36, 3056-3060.
64. Johnson, W.W., Yamazaki, H., Shimada, T., Ueng, Y.F. and Guengerich, F.P. (1997b) Aflatoxin B1 8,9-epoxide hydrolysis in the presence of rat and human epoxide hydrolase. Chem. Res. Toxicol., 10, 672-676.
65. Judah, D.J., Hayes, J.D., Yang, J.C., Lian, L.Y, Roberts, G.C., Farmer, P.B., Lamb, J.H. and Neal, G.E. (1993) A novel aldehyde reductase with activity towards a metabolite of aflatoxin B1 is expressed in rat liver during carcinogenesis and following the administration of an anti-oxidant. Biochem. J., 292, 13-18.
66. Kamataki, T., Hashimoto, H., Shimoji, M., Itoh, S., Nakayama, K., Hattori, K., Yokoi, T., Katsuki, M. and Aizawa, S. (1995) Expression of CYP3A7, a human fetus-specific cytochrome P450, in cultured cells and in the hepatocytes of p53-knockout mice. Toxicol. Lett., 82/83, 879-882.
67. Kaplanski, C., Chisari, F.V. and Wild, C.P. (1997) Minisatellite rearrangements are increased in liver tumours induced by transplacental aflatoxin B1 treatment of hepatitis B virus transgenic mice, but not in spontaneously arising tumours. Carcinogenesis, 18, 633-639.
68. Katiyar, S., Dash, B.C., Thakur, V., Guptan, R.C., Sarin, S.K. and Das, B.C. (2000) P53 tumor suppressor gene mutations in hepatocellular carcinoma patients in India. Cancer, 88, 1565-1573.
69. Kazachkov, Y., Khaoustov, V., Yoffe, B., Solomon, H., Klintmalm, G.B.G. and Tabor, E. (1996) p53 abnormalities in hepatocellular carcinoma from United States patients: analysis of all 11 exons. Carcinogenesis, 17, 2207-2212.
70. Kensler, T.W., Egner, P.A., Davidson, N.E., Roebuck, B.D., Pikul, A. and Groopman, J.D. (1986) Modulation of aflatoxin metabolism, aflatoxin-N7-guanine formation, and hepatic tumorigenesis in rats fed ethoxyquin: role of induction of glutathione S-transferases. Cancer Res., 46, 3924-3931.
71. Kensler, T.W., Gange, S.J., Egner, P.A., Dolan, P.M., Munoz, A., Groopman, J.D., Rogers, A.E. and Roebuck, B.D. (1997) Predictive value of molecular dosimetry: individual versus group effects of oltipraz on aflatoxin-albumin adducts and risk of liver cancer. Cancer Epidemiol. Biomarkers Prev., 6, 603-610.
72. Kensler, T.W., He, X., Otieno, M. et al. (1998) Oltipraz chemoprevention trial in Qidong, People's Republic of China: modulation of serum aflatoxin albumin adduct biomarkers. Cancer Epidemiol. Biomarkers Prev., 7, 127-134.
73. Kirby, G.M., Wolf, C.R., Neal, G.E., Judah, D.J., Henderson, C.J., Srivatanakul, P. and Wild, C.P. (1993) In vitro metabolism of aflatoxin B1 by normal and tumorous liver tissue from Thailand. Carcinogenesis, 14, 2613-2620.
74. Kirby, G.M., Chemin, I., Montesano, R., Chisari, F.V., Lang, M.A. and Wild, C.P. (1994a) Induction of specific cytochrome P450s involved in aflatoxin B1 metabolism in hepatitis B virus transgenic mice. Mol. Carcinog., 11, 74-80.
75. Kirby, G.M., Pelkonen, P., Vatanasapt, V., Camus, A.M., Wild, C.P. and Lang, M.A. (1994b) Association of liver fluke (Opisthorchis viverrini) infestation with increased expression of cytochrome P450 and carcinogen metabolism in male hamster liver. Mol. Carcinog., 11, 81-89.
76. Kirk, G.D., Camus-Randon, A.M., Mendy, M., Goedert, J.J., Merle, P., Trepo, C., Brechot, C., Hainaut, P. and Montesano, R. (2000) Ser-249 p53 mutations in plasma DNA of patients with hepatocellular carcinoma from The Gambia. J. Natl Cancer Inst., 92, 148-153.
77. Kitada, M., Taneda, M., Ohi, H., Komori, M., Itahashi, K., Nagao, M. and Kamataki, T. (1989) Mutagenic activation of aflatoxin B1 by P-450 HFLa in human fetal livers. Mutat. Res., 227, 53-58.
78. Knight, L.P., Primiano, T., Groopman, J.D., Kensler, T.W. and Sutter, T.R. (1999) cDNA cloning, expression and activity of a second human aflatoxin B1-metabolizing member of the aldo-keto reductase superfamily, AKR7A3. Carcinogenesis, 20, 1215-1223.
79. Kobertz, W.R., Wang, D., Wogan, G.N. and Essigmann, J.M. (1997) An intercalation inhibitor altering the target selectivity of DNA damaging agents: synthesis of site-specific aflatoxin B1 adducts in a p53 mutational hotspot. Proc. Natl Acad. Sci. USA, 94, 9579-9584.
80. Koulibaly, M., Kabba, I.S., Cisse, A., Diallo, S.B., Diallo, M.B., Keita, N., Camara, N.D., Diallo, M.S., Sylla, B,S, and Parkin, D.M. (1997) Cancer incidence in Conakry, Guinea: first results from the Cancer Registry 1992-1995. Int. J. Cancer, 70, 39-45.
81. Konishi, M., Kikuchiyanoshita, R., Tanaka, K. et al. (1993) Genetic changes and histopathological grades in human hepatocellular carcinomas. Jpn. J. Cancer Res., 84, 893-899.
82. Kolars, J.C., Benedict, P., Schmiedlin Ren, P. and Watkins, P.B. (1994) Aflatoxin B1-adduct formation in rat and human small bowel enterocytes. Gastroenterology, 106, 433-439.
83. Kress, S., Jahn, U.R., Buchmann, A., Bannasch, P. and Schwarz, M. (1992) p53 mutations in human hepatocellular carcinomas from Germany. Cancer Res., 52, 3220-3223.
84. Kubicka, S., Trautwein, C., Schrem, H., Tillmann, H. and Manns, M. (1995) Low incidence of p53 mutations in European hepatocellular carcinomas with heterogeneous mutation as a rare event. J. Hepatol., 23, 412-419.
85. Kuehl, P., Zhang, J., Lin, Y. et al. (2001) Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nature Genet., 27, 383-391.
86. Langouet, S., Coles, B., Morel, F., Becquemont, L., Beaune, P., Guengerich, F.P., Ketterer, B. and Guillouzo, A. (1995) Inhibition of CYP1A2 and CYP3A4 by oltipraz results in reduction of aflatoxin B1 metabolism in human hepatocytes in primary culture. Cancer Res., 55, 5574-5579.
87. Lasky, T. and Magder, L. (1997) Hepatocellular carcinoma p53 G→T transversions at codon 249: the fingerprint of aflatoxin exposure? Environ. Health Perspect., 105, 392-397.
88. Laurent-Puig, P., Legoix, P., Bluteau, O., Belghiti, J., Franco, D., Binot, F., Monges, G., Thomas, G., Bioulac-Sage, P. and Zucman-Rossi, J. (2001) Genetic alterations associated with hepatocellular carcinomas define distinct pathways of hepatocarcinogenesis. Gastroenterology, 120, 1763-1773.
89. Lee, C.C., Liu, J.Y., Lin, J.K., Chu, J.S. and Shew, J.Y. (1998) p53 point mutation enhanced by hepatic regeneration in aflatoxin B1-induced rat liver tumors and preneoplastic lesions. Cancer Lett., 125, 1-7.
90. Levy, D.D., Groopman, J.D., Lim, S.E., Seidman, M.M. and Kraemer, K.H. (1992) Sequence specificity of aflatoxin B1-induced mutations in a plasmid replicated in xeroderma, pigmentosum and DNA repair proficient human cells. Cancer Res., 52, 5668-5673.
91. Li, D., Cao, Y., He, L., Wang, N.J. and Gu, J.R. (1993) Aberrations of p53 gene in human hepatocellular carcinoma from China. Carcinogenesis, 14, 169-173.
92. Li, Y., Su, J., Qin, L., Egner, P.A., Wang, J., Groopman, J.D., Kensler, T.W. and Roebuck, B.D. (2000) Reduction of aflatoxin B(1) adduct biomarkers by oltipraz in the tree shrew (Tupaia belangeri chinensis). Cancer Lett., 154, 79-83.
93. Lunn, R.M., Zhang, Y.J., Wang, L.Y., Chen, C.J., Lee, P.H., Lee, C.S., Tsai, W.Y. and Santella, R.M. (1997) p53 mutations, chronic hepatitis B virus infection, and aflatoxin exposure in hepatocellular carcinoma in Taiwan. Cancer Res., 57, 3471-3477.
94. Lunn, R.M., Langlois, R.G., Hsieh, L.L., Thompson, C.L. and Bell, D.A. (1999) XRCC1 polymorphisms: effects on aflatoxin B1-DNA adducts and glycophorin A variant frequency. Cancer Res., 59, 2557-2561.
95. McLean, M. and Dutton, M.F. (1995) Cellular interactions and metabolism of aflatoxin: an update. Pharmacol. Ther., 65, 163-192.
96. Montesano, R., Hainaut, P. and Wild, C.P. (1997) Hepatocellular carcinoma: from gene to public health. J. Natl Cancer Inst., 89, 1844-1851.
97. Morel, F., Fardel, O., Meyer, D.J., Langouet, S., Gilmore, K.S., Meunier, B., Tu, C.P., Kensler, T.W., Ketterer, B. and Guillouzo, A. (1993) Preferential increase of glutathione S-transferase class alpha transcripts in cultured human hepatocytes by phenobarbital, 3-methylcholanthrene, and dithiolethiones. Cancer Res., 53, 231-234.
98. Moss, E.J. and Neal, G.E. (1985) The metabolism of aflatoxin B1 by human liver. Biochem. Pharmacol., 34, 3193-3197.
99. Murakami, Y., Hayashi, K., Hirohashi, S. and Sekiya, T. (1991) Aberrations of the tumor suppressor p53 and retinoblastoma genes in human hepatocellular carcinomas. Cancer Res., 51, 5520-5525.
100. Nishida, N., Fukuda, Y., Kokuryu, H., Toguchida, J., Yandell, D.W., Ikenega, M., Imura, H. and Ishizaki, K. (1993) Role and mutational heterogeneity of the p53 gene in hepatocellular carcinoma. Cancer Res., 53, 368-372.
101. Ng, I.O., Chung, L.P., Tsang, S.W., Lam, C.L., Lai, E.C., Fan, S.T. and Ng, M. (1994a) p53 gene mutation spectrum in hepatocellular carcinomas in Hong Kong Chinese. Oncogene, 9, 985-990.
102. Ng, I.O., Srivastava, G., Chung, L.P., Tsang, S.W. and Ng, M.M. (1994b) Overexpression and point mutations of p53 tumor suppressor gene in hepatocellular carcinomas in Hong Kong Chinese people. Cancer, 74, 30-37.
103. Nose, H., Imazeki, F., Ohto, M. and Omata, M. (1993) p53 gene mutations and 17p allelic deletions in hepatocellular carcinoma from Japan. Cancer, 72, 355-360.
104. Oda, T., Tsuda, H., Scarpa, A., Sakamoto, M. and Hirohashi, S. (1992) p53 gene mutation spectrum in hepatocellular carcinoma. Cancer Res., 52, 6358-6364.
105. Ozturk, M. (1991) p53 mutation in hepatocellular carcinoma after aflatoxin exposure. Lancet, 338, 1356-1359.
106. Park, U.S., Su, J.J., Ban, K.C., Qin, L., Lee, E.H. and Lee, Y.I. (2000) Mutations in the p53 tumor suppressor gene in tree shrew hepatocellular carcinoma associated with hepatitis B virus infection and intake of aflatoxin B1. Gene, 251, 73-80.
107. Park, Y.M., Yoo, Y.D., Paik, S.Y., Kim, B.S. and Tabor, E. (1996) Mutation of tumor suppressor gene p53 in hepatocelluclar carcinomas from Korea. Exp. Mol. Med., 28, 173-179.
108. Ponchel, F., Puisieux, A., Tabone, E., Michot, J.P., Froschl, G., Morel, A.P., Frebourg, T., Fontaniere, B., Oberhammer, F. and Ozturk, M. (1994) Hepatocarcinoma-specific mutant p53-249ser induces mitotic activity but has no effect on transforming growth factor beta 1-mediated apoptosis. Cancer Res., 54, 2064-2068.
109. Puisieux, A., Lim, S., Groopman, J. and Ozturk, M. (1991) Selective targeting of p53 gene mutational hotspots in human cancers by etiologically defined carcinogens. Cancer Res., 51, 6185-6189.
110. Qian, G.S., Ross, R.K., Yu, M.C., Yuan, J.M., Gao, Y.T., Henderson, B.E., Wogan, G.N. and Groopman, J.D. (1994) A follow-up study of urinary markers of aflatoxin exposure and liver cancer risk in Shanghai, People's Republic of China. Cancer Epidemiol. Biomarkers Prev., 3, 3-10.
111. Raney, K.D., Gopalakrishnan, S., Byrd, S., Stone, M.P. and Harris, T.M. (1990) Alteration of the aflatoxin cyclopentenone ring to a delta-lactone reduces intercalation with DNA and decreases formation of guanine N7 adducts by aflatoxin epoxides. Chem. Res. Toxicol., 3, 254-261.
112. Raney, K.D., Meyer, D.J., Ketterer, B., Harris, T.M. and Guengerich, F.P. (1992) Glutathione conjugation of aflatoxin B1 exo- and endo-epoxides by rat and human glutathione S-transferases. Chem. Res. Toxicol., 5, 470-478.
113. Raney, V.M., Harris, T.M. and Stone, M.P. (1993) DNA conformation mediates aflatoxin B1-DNA binding and the formation of guanine N7 adducts by aflatoxin-B1 8,9-exo-epoxide. Chem. Res. Toxicol., 6, 64-68.
114. Rivkina, M., Cullen, J.M., Robinson, W.S. and Marion, P.L. (1994) State of the p53 gene in hepatocellular carcinomas of ground squirrels and woodchucks with past and ongoing infection with hepadnaviruses. Cancer Res., 54, 5430-5437.
115. Rivkina, M., Cote, P.J., Robinson, W.S., Tennant, B.C. and Marion, P.L. (1996) Absence of mutations in the p53 tumour suppressor gene in woodchuck hepatocellular carcinomas associated with hapadnavirus infection and intake of aflatoxin B1. Carcinogenesis, 17, 2689-2694.
116. Roebuck, B.D., Liu, Y.L., Rogers, A.E., Groopman, J.D. and Kensler, T.W. (1991) Protection against aflatoxin B1-induced hepatocarcinogenesis in F344 rats by 5-(2-pyrazinyl)-4-methyl-1,2-dithiole-3-thione (oltipraz): predictive role for short-term molecular dosimetry. Cancer Res., 51, 5501-5506.
117. Ross, R.K., Yuan, J.M., Yu, M.C., Wogan, G.N., Qian, G.S., Tu, J.T., Groopman, J.D., Gao, Y.T. and Henderson, B.E. (1992) Urinary aflatoxin biomarkers and risk of hepatocellular carcinoma. Lancet, 339, 943-946.
118. Sabbioni, G. and Wild, CP (1991) Identification of an aflatoxin G1-serum albumin adduct and its relevance to the measurement of human exposure to aflatoxins. Carcinogenesis, 12, 97-103.
119. Sabbioni, G., Skipper, P.L., Buchi, G. and Tannenbaum, S.R. (1987) Isolation and characterization of the major serum albumin adduct formed by aflatoxin B1 in vivo in rats. Carcinogenesis, 8, 819-824.
120. Schleger, C., Becker, R., Oesch, F. and Steinberg, P. (1999) The human p53 gene mutated at position 249 per se is not sufficient to immortalize human liver cells. Hepatology, 29, 834-838.
121. Scorsone, K.A., Zhou, Y.Z., Butel, J.S. and Slagle, B.L. (1992) p53 mutations cluster at codon 249 in hepatitis B virus-positive hepatocellular carcinomas from China. Cancer Res., 52, 1635-1638.
122. Sell, S., Hunt, J.M., Dunsford, H.A. and Chisari, F.V. (1991) Synergy between hepatitis B virus expression and chemical hepatocarcinogens in transgenic mice. Cancer Res., 51, 1278-1285.
123. Shi, C.Y., Phang, T.W., Lin, Y., Wae, A., Li, B., Lee, H.P., Ong, C.N. (1995) Codon-249 mutation on the p53 gene is a rare event in hepatocellular carcinomas from ethnic Chinese in Singapore. Brit. J. Cancer, 72(1), 146-149.
124. Shimizu, Y., Zhu, J.J., Han, F., Ishikawa, T. and Oda, H. (1999) Different frequencies of p53 codon-249 hot-spot mutations in hepatocellular carcinomas in Jiang-su province of China. Int. J. Cancer, 82, 187-190.
125. Smela, M.E., Currier, S.S., Bailey, E.A. and Essigmann, J.M. (2001) The chemistry and biology of aflatoxin B1: from mutational spectrometry to carcinogenesis. Carcinogenesis, 22, 535-545.
126. Sohn, S., Jaitovitch-Groisman, I., Benlimame, N., Galipeau, J., Batist, G. and Alaoui-Jamali, M.A. (2000) Retroviral expression of the hepatitis B virus x gene promotes liver cell susceptibility to carcinogen-induced site specific mutagenesis. Mutat. Res., 460, 17-28.
127. Soini, Y., Chia, S.C., Bennett, W.P. et al. (1996) An aflatoxin-associated mutational hotspot at codon 249 in the p53 tumor suppressor gene occurs in hepatocellular carcinomas from Mexico. Carcinogenesis, 17, 1007-1012,
128. Stern, M.C., Umbach, D.M., Yu, M.C., London, S.J., Zhang, Z.Q. and Taylor, J.A. (2001) Hepatitis B, aflatoxin B, and p53 codon 249 mutation in hepatocellular carcinomas from Guangxi, People's Republic of China, and a meta-analysis of existing studies. Cancer Epidemiol. Biomarkers Prev., 10, 617-625.
129. Stettler, P.M. and Sengstag, C. (2001) Liver carcinogen aflatoxin B1 as an inducer of mitotic recombination in a human cell line. Mol. Carcinog., 31, 125-138.
130. Sylla, A., Diallo, M.S., Castegnaro, J. and Wild, C.P. (1999) Interactions between hepatitis B virus infection and exposure to aflatoxins in the development of hepatocellular carcinoma; a molecular epidemiological approach. Mutat. Res., Fund Mol. M. 428(1-2): 187-196.
131. Sun, C.A., Chen, H.C., Lu, S.N., Chen, C.J., Lu, C.F., You, S.L. and Lin, S.H. (2001) Persistent hyperendemicity of hepatitis C virus infection in Taiwan: the important role of iatrogenic risk factors. J. Med. Virol., 65, 30-34.
132. Tanaka, S., Toh, Y., Adachi, E., Matsumata, T., Mori, R. and Sugimachi, K. (1993) Tumor progression in hepatocellular-carcinoma may be mediated by p53 mutation. Cancer Res., 53, 2884-2887.
133. Teramoto, T., Satonaka, K., Kitazawa, S., Fujimori, T., Hayashi, K. and Maeda, S. (1994) p53 gene abnormalities are closely-related to hepatoviral infections and occur at a late-stage of hepatocarcinogenesis. Cancer Res., 54, 231-235.
134. Trottier, Y., Waithe, W.I. and Anderson, A. (1992) Kinds of mutations induced by aflatoxin B1 in a shuttle vector replicating in human cells transiently expressing cytochrome P4501A2 cDNA. Mol. Carcinog., 6, 140-147.
135. Turner, P.C., Mendy, M., Whittle, H., Fortuin, M., Hall, A.J. and Wild, C.P. (2000) Hepatitis B infection and aflatoxin biomarker levels in Gambian children. Trop. Med. Int. Health, 5, 837-841.
136. Ueng, Y.F., Shimada, T., Yamazaki, H. and Guengerich, F.P. (1995) Oxidation of aflatoxin B1 by bacterial recombinant human cytochrome P450 enzymes. Chem. Res. Toxicol., 8, 218-225.
137. Vautier, G., Bomford, A.B., Portmann, B.C., Metivier, E., Williams, R. and Ryder, S.D. (1999) p53 mutations in British patients with hepatocellular carcinoma: clustering in genetic hemochromatosis. Gastroenterology, 117, 154-160.
138. Wang, H., Dick, R., Yin, H., Licad-Coles, E., Kroetz, D.L., Szklarz, G., Harlow, G., Halpert, J.R. and Correia, M.A. (1998) Structure-function relationships of human liver cytochromes P450 3A: aflatoxin B1 metabolism as a probe. Biochemistry, 37, 12536-12545.
139. Wang, J.S., Qian, G.S., Zarba, A. et al. (1996) Temporal patterns of aflatoxin-albumin adducts in hepatitis B surface antigen-positive and antigen-negative residents of Daxin, Qidong County, People's Republic of China. Cancer Epidemiol. Biomarkers Prev., 5, 253-261.
140. Wang, J.S., Shen, X., He, X. et al. (1999) Protective alterations in phase 1 and 2 metabolism of aflatoxin B1 by oltipraz in residents of Qidong, People's Republic of China. J. Natl Cancer Inst., 91, 347-354.
141. Wang, L.Y., Hatch, M., Chen, C.J. et al. (1996) Aflatoxin exposure and risk of hepatocellular carcinoma in Taiwan. Int. J. Cancer, 67, 620-625.
142. Wild, C.P. and Hall, A.J. (1999) Hepatitis B virus and liver cancer: unanswered questions. Cancer Surv., 33, 35-54.
143. Wild, C.P. and Hall, A.J. (2000) Primary prevention of hepatocellular carcinoma in developing countries. Mutat. Res., 462, 381-393.
144. Wild, C.P. and Kleihues, P. (1996) Etiology of cancer in humans and animals. Exp. Toxicol. Pathol., 48, 95-100.
145. Wild, C.P. and Turner, P.C. (2001) Exposure biomarkers in chemoprevention studies of liver cancer. In Miller, A.B., Bartsch, H., Bofetta, P., Dragsted, L. and Vanio, H. (eds), Biomarkers in Cancer Chemoprevention, IARC Scientific Publications no. 154. IARC, Lyon, pp. 215-222.
146. Wild, C.P., Rasheed, F.N., Jawla, M.F., Hall, A.J., Jansen, L.A. and Montesano, R. (1991) In-utero exposure to aflatoxin in west Africa. Lancet, 337, 1602.
147. Wild, C.P., Fortuin, M., Donato, F., Whittle, H.C., Hall, A.J., Wolf, C.R. and Montesano, R. (1993) Aflatoxin, liver enzymes, and hepatitis B virus infection in Gambian children. Cancer Epidemiol. Biomarkers Prev., 2, 555-561.
148. Wild, C.P., Hasegawa, R., Barraud, L., Chutimataewin, S., Chapot, B., Ito, N. and Montesano, R. (1996) Aflatoxin albumin adducts - a basis for comparative carcinogenesis between animals and humans. Cancer Epidemiol. Biomarkers Prev., 5, 179-189.
149. Wild, C.P., Yin, F., Turner, P.C., Chemin, I., Chapot, B., Mendy, M., Whittle, H., Kirk, G.D. and Hall, A. (2000) Environmental and genetic determinants of aflatoxin-albumin adducts in The Gambia. Int. J. Cancer, 86, 1-7.
150. Wong, N., Lai, P., Pang, E. et al. (2000) Genomic aberrations in human hepatocellular carcinomas of differing etiologies. Clin. Cancer Res., 6, 4000-4009.
151. Yamada, A., Fujita, K., Yokoi, T., Muto, S., Suzuki, A., Gondo, Y., Katsuki, M. and Kamataki, T. (1998) In vivo detection of mutations induced by aflatoxin B1 using human CYP3A7/HITEC hybrid mice. Biochem. Biophys. Res. Commun., 250, 150-153.
152. Yang, M., Zhou, H., Kong, R.Y., Fong, W.F., Ren, L.Q., Liao, X.H., Wang, Y., Zhuang, W. and Yang, S. (1997) Mutations at codon 249 of P53 gene in human hepatocellular carcinomas from Tongan, China. Mutat. Res., 381, 25-29.
153. Zhou, T., Evans, A.A., London, W.T., Xia, X., Zou, H., Shen, F. and Clapper, M.L. (1997) Glutathione S-transferase expression in hepatitis B virus-associated human hepatocellular carcinogenesis. Cancer Res., 57, 2749-2753.